Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrainSTEADy: Amygdala fMRI-BOLD Neurofeedback in Borderline Personality Disorder
NCT06626789Phase 2Recruiting
- Sponsor
- Central Institute of Mental Health
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in borderline personality disorder (BPD) (2 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Affect Intensity. Started Apr 2025; status: recruiting.
02
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT06626789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06626789.